Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-Cell responses

Journal of Neuropathology and Experimental Neurology

Volumn 71, Issue 11, 2012, Pages 983-999

  MacMillan, Carolyn J ^a   Furlong, Suzanne J ^a   Doucette, Carolyn D ^a   Chen, Pei Lin ^a   Hoskin, David W ^a   Easton, Alexander S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Angiopoietin; Bevacizumab; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Permeability; T cell; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 2; BEVACIZUMAB; CD4 ANTIGEN; ENDOGLIN; GAMMA INTERFERON; INTERLEUKIN 17; MESSENGER RNA; VASCULOTROPIN;

ALLERGIC ENCEPHALOMYELITIS; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; LYMPH NODE; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD; T LYMPHOCYTE; TH1 CELL; TH17 CELL; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPITOPES, T-LYMPHOCYTE; FEMALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; SEVERITY OF ILLNESS INDEX; SPINAL CORD;

EID: 84871218238     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3182724831     Document Type: Article

References (41)

1. Kirk SL, Karlik SJ. VEGF and vascular changes in chronic neuroinflammation. J Autoimmun 2003;21:353-63
2. Roscoe WA, Welsh ME, Carter DE, et al. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptideYinduced EAE. J Neuroimmunol 2009;209:6-15
3. Seabrook TJ, Littlewood-Evans A, Brinkmann V, et al. Angiogenesis is present in experimental autoimmune encephalomyelitis and proangiogenic factors are increased in multiple sclerosis lesions. J Neuroinflammation 2010;7:95
4. Macmillan CJ, Starkey RJ, Easton AS. Angiogenesis is regulated by angiopoietins during experimental autoimmune encephalomyelitis and is indirectly related to vascular permeability. J Neuropathol Exp Neurol 2011; 70:1107-23
5. Kobayashi H, Lin PC. Angiopoietin/Tie2 signaling, tumor angiogenesis and inflammatory diseases. Front Biosci 2005;10:666-74
6. Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010;10:575-85
7. Bar-Or A. Immunology of multiple sclerosis. Neurol Clin 2005;23: 149-75.
8. Peterson JW, Trapp BD. Neuropathobiology of multiple sclerosis. Neurol Clin 2005;23:107-29
9. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antiYvascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-99
10. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
11. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-35
12. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007;48:2545-52
13. Avisar I, Weinberger D, Kremer I. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model. Curr Eye Res 2010;35:108-15
14. Bock F, Onderka J, Rummelt C, et al. Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 2009;50: 2095-102
15. Dastjerdi MH, Saban DR, Okanobo A, et al. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci 2010;51:2411-17
16. Dastjerdi MH, Sadrai Z, Saban DR, et al. Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 2011;52: 8718-23
17. Dratviman-Storobinsky O, Lubin BC, Hasanreisoglu M, et al. Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization. Mol Vis 2009;15:2326-38
18. Lin CT, Hu FR, Kuo KT, et al. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency. Invest Ophthalmol Vis Sci 2010;51:6277-85
19. Teixeira LR, Vargas FS, Acencio MM, et al. Blockage of vascular endothelial growth factor (VEGF) reduces experimental pleurodesis. Lung Cancer 2011;74:392-95
20. Rezaeian F, Wettstein R, Egger JF, et al. Erythropoietin-induced upregulation of endothelial nitric oxide synthase but not vascular endothelial growth factor prevents musculocutaneous tissue from ischemic damage. Lab Invest 2010;90:40-51
21. Yang H, Jager MJ, Grossniklaus HE. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci 2010;51:2835-42
22. Barzelay A, Lowenstein A, George J, et al. Influence of nontoxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis. Curr Eye Res 2010;35:835-41
23. Eveno C, Gaujoux S, Tobelem G, et al. Did animal offer relevant model for bevacizumab testing? Br J Cancer 2008;99:1555
24. Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: A reassessment. Invest Ophthalmol Vis Sci 2008;49: 522-27
25. Liang WC, Wu X, Peale FV, et al. Cross-species vascular endothelial growth factor (VEGF)Yblocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006;281:951-61
26. Stromnes IM, Goverman JM. Active induction of experimental allergic encephalomyelitis. Nat Protoc 2006;1:1810-19
27. Gauden V, Hu DE, Kurokawa T, et al. Novel technique for estimating cerebrovascular permeability demonstrates capsazepine protection following ischemia-reperfusion. Microcirculation 2007;14:767-78
28. Joice SL, Mydeen F, Couraud P-O, et al. Modulation of blood-brain barrier permeability by neutrophils: In vitro and in vivo studies. Brain Res 2009;1298:13-23
29. Rapoport SI. A mathematical model for vasogenic brain edema. J Theor Biol 1978;74:439-67
30. Fuh G, Wu P, Liang WC, et al. Structure-function studies of two synthetic antiYvascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 2006;281:6625-31
31. Fonsatti E, Sigalotti L, Arslan P, et al. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets 2003;3:427-32
32. Duff SE, Li C, Garland JM, et al. CD105 is important for angiogenesis: Evidence and potential applications. FASEB J 2003;17:984-92
33. Schlageter KE, Molnar P, Lapin GD, et al. Microvessel organization and structure in experimental brain tumors: Microvessel populations with distinctive structural and functional properties. Microvasc Res 1999;58: 312-28
34. Easton AS, Sarker MH, Fraser PA. Two components of blood-brain barrier disruption in the rat. J Physiol 1997;503:613-23
35. Easton AS, Fraser PA. Variable restriction of albumin diffusion across inflamed cerebral microvessels of the anaesthetized rat. J Physiol 1994; 475:147-57
36. Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000;106:829-38
37. El-behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol 2010;5:189-97
38. Weller RO, Djuanda E, Yow H, et al. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 2009; 117:1-14
39. Stefanini MO, Wu FT, Mac Gabhann F, et al. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res 2010;70:9886-94
40. Mor F, Quintana F, Cohen I. Angiogenesis-inflammation cross-talk: Vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol 2004;172:4618-23
41. Roland CL, Dineen SP, Lynn KD, et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 2009;8: 1761-71